{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:18:17Z","timestamp":1785860297158,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004569","name":"Ministerstwo Edukacji i Nauki","doi-asserted-by":"publisher","award":["Innovation Incubator 2.0 programme; grant no. MNISW\/2017\/DIR\/71\/II+"],"award-info":[{"award-number":["Innovation Incubator 2.0 programme; grant no. MNISW\/2017\/DIR\/71\/II+"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostaglandin F2\u03b1 receptor (FP receptor) signaling is a plausible target for promoting hair growth, but clinical data on topical latanoprost acid (the active free-acid FP agonist) in hair loss are lacking. This study aimed to evaluate the clinical efficacy, safety, and mechanistic basis of topical latanoprost acid in women with female androgenetic alopecia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this investigator-initiated, randomized, double-blind, single-center, dose-ranging pilot trial, 29 adult women with hair loss predominantly consistent with female androgenetic alopecia were randomized to vehicle (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092) or topical latanoprost acid 0.01% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098), 0.05% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200913), or 0.1% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096), applied once daily for 6 months. The primary endpoint was within-participant change in target-area hair count (TAHC, hairs\/cm\u00b2) from baseline to month 6; trichoscopic activity markers (yellow dots) and follicular-unit (FU) remodeling were secondary and exploratory outcomes. Human hair dermal papilla cells (HHDPCs) were assessed for FP receptor-linked signaling (intracellular Ca\u00b2\u207a flux) and DNA synthesis by 5-ethynyl-2\u2032-deoxyuridine (EdU) incorporation after exposure to latanoprost acid versus equimolar latanoprost.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>An increase in TAHC was observed across all active treatment arms (mean\u2009\u00b1\u2009SEM \u0394TAHC: 17.8\u2009\u00b1\u20094.3, 23.5\u2009\u00b1\u20096.1, and 16.5\u2009\u00b1\u20096.5 hairs\/cm\u00b2 in the latanoprost acid 0.01%, 0.05%, and 0.1% arms, respectively). No significant between-arm differences were detected. Secondary and exploratory trichoscopic analyses showed reductions in yellow-dot counts, a decrease in single-hair FUs, and an increase in triple-hair FUs. Safety was favorable, with no serious adverse events. In mechanistic assays, latanoprost acid triggered rapid, concentration-dependent Ca\u00b2\u207a flux, whereas equimolar latanoprost produced delayed signals; neither compound altered EdU incorporation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this pilot proof-of-concept trial, topical latanoprost acid showed a coherent clinical-trichoscopic bioactivity signal, supported by FP receptor-linked signaling in HHDPCs. These findings require confirmation in larger randomized pharmacokinetic\/pharmacodynamic-integrated trials designed to optimize dose, confirm efficacy, and further characterize long-term safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT07412587; registered on February 2, 2026.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43440-026-00876-0","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T08:59:32Z","timestamp":1783673972000},"page":"1236-1249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Topical latanoprost acid for female androgenetic alopecia: a pilot proof-of-concept trial with mechanistic evidence of prostaglandin F2\u03b1 receptor activation"],"prefix":"10.1007","volume":"78","author":[{"given":"Adriana","family":"Rakowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Dutkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliwia","family":"Zegrocka-Stendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Dymkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Huszcza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Wierzbicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Walczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Rudnicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Koziak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"4","key":"876_CR1","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.abd.2022.09.006","volume":"98","author":"P Muller Ramos","year":"2023","unstructured":"Muller Ramos P, Melo DF, Radwanski H, de Almeida RFC, Miot HA. Female-pattern hair loss: therapeutic update. Bras Dermatol. 2023;98(4):506\u201319.","journal-title":"Bras Dermatol"},{"key":"876_CR2","doi-asserted-by":"crossref","unstructured":"Mohamed NE, Soltan MR, Galal SA, El Sayed HS, Hassan HM, Khatery BH. Female pattern hair loss and negative psychological impact: possible role of brain-derived neurotrophic factor (BDNF). Dermatol Pract Concept. 2023;13(3).","DOI":"10.5826\/dpc.1303a139"},{"issue":"3","key":"876_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jdermsci.2021.01.007","volume":"101","author":"GO Chien Yin","year":"2021","unstructured":"Chien Yin GO, Siong-See JL, Wang ECE. Telogen Effluvium - a review of the science and current obstacles. J Dermatol Sci. 2021;101(3):156\u201363.","journal-title":"J Dermatol Sci"},{"issue":"4","key":"876_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jaad.2003.06.014","volume":"50","author":"AW Lucky","year":"2004","unstructured":"Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541\u201353.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"876_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/jdv.14624","volume":"32","author":"V Kanti","year":"2018","unstructured":"Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol Venereol. 2018;32(1):11\u201322.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"876_CR6","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jaad.2025.04.074","volume":"93","author":"MM Ong","year":"2025","unstructured":"Ong MM, Avram M, McMichael A, Tosti A, Lipner SR. Antiandrogen therapy for the treatment of female pattern hair loss: A clinical review of current and emerging therapies. J Am Acad Dermatol. 2025;93(3):749\u201360.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"876_CR7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S0002-9394(14)70870-0","volume":"124","author":"MA Johnstone","year":"1997","unstructured":"Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124(4):544\u20137.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"876_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1600-0625.2007.00639.x","volume":"17","author":"L Colombe","year":"2008","unstructured":"Colombe L, Michelet JF, Bernard BA. Prostanoid receptors in anagen human hair follicles. Exp Dermatol. 2008;17(1):63\u201372.","journal-title":"Exp Dermatol"},{"issue":"2","key":"876_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1006\/bbrc.1994.1515","volume":"200","author":"S Ito","year":"1994","unstructured":"Ito S, Sakamoto K, Mochizuki-Oda N, Ezashi T, Miwa K, Okuda-Ashitaka E, et al. Prostaglandin F2 alpha receptor is coupled to Gq in cDNA-transfected Chinese hamster ovary cells. Biochem Biophys Res Commun. 1994;200(2):756\u201362.","journal-title":"Biochem Biophys Res Commun"},{"key":"876_CR10","doi-asserted-by":"crossref","unstructured":"Carruthers J, Beer K, Carruthers A, Coleman WP 3rd, Draelos ZD, Jones D, et al. Bimatoprost 0.03% for the treatment of eyebrow hypotrichosis. Dermatol Surg. 2016;42(5):608\u201317.","DOI":"10.1097\/DSS.0000000000000755"},{"issue":"5","key":"876_CR11","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jaad.2011.05.026","volume":"66","author":"U Blume-Peytavi","year":"2012","unstructured":"Blume-Peytavi U, Lonnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012;66(5):794\u2013800.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"876_CR12","first-page":"1134","volume":"42","author":"JW Stjernschantz","year":"2001","unstructured":"Stjernschantz JW. From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. Invest Ophthalmol Vis Sci. 2001;42(6):1134\u201345.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Suppl 1","key":"876_CR13","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/S0039-6257(02)00323-5","volume":"47","author":"KM Maxey","year":"2002","unstructured":"Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol. 2002;47(Suppl 1):S34\u201340.","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"876_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000501732","volume":"32","author":"SM Pyo","year":"2019","unstructured":"Pyo SM, Maibach HI. Skin Metabolism: Relevance of Skin Enzymes for Rational Drug Design. Skin Pharmacol Physiol. 2019;32(5):283\u201394.","journal-title":"Skin Pharmacol Physiol"},{"key":"876_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/metabo13080934","volume":"13","author":"KC Telaprolu","year":"2023","unstructured":"Telaprolu KC, Grice JE, Mohammed YH, Roberts MS. Human Skin Drug Metabolism: Relationships between Methyl Salicylate Metabolism and Esterase Activities in IVPT Skin Membranes. Metabolites. 2023;13:8.","journal-title":"Metabolites"},{"issue":"Suppl 1","key":"876_CR16","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/S0039-6257(02)00302-8","volume":"47","author":"B Sjoquist","year":"2002","unstructured":"Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47(Suppl 1):S6\u201312.","journal-title":"Surv Ophthalmol"},{"issue":"12","key":"876_CR17","doi-asserted-by":"publisher","first-page":"20780","DOI":"10.3390\/molecules191220780","volume":"19","author":"DD N\u2019Da","year":"2014","unstructured":"N\u2019Da DD. Prodrug strategies for enhancing the percutaneous absorption of drugs. Molecules. 2014;19(12):20780\u2013807.","journal-title":"Molecules"},{"issue":"2","key":"876_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4103\/0974-7753.58555","volume":"1","author":"A Rakowska","year":"2009","unstructured":"Rakowska A, Slowinska M, Kowalska-Oledzka E, Olszewska M, Rudnicka L. Dermoscopy in female androgenic alopecia: method standardization and diagnostic criteria. Int J Trichology. 2009;1(2):123\u201330.","journal-title":"Int J Trichology"},{"issue":"5","key":"876_CR19","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1590\/abd1806-4841.20176157","volume":"92","author":"CDS Lima","year":"2017","unstructured":"Lima CDS, Lemes LR, Melo DF. Yellow dots in trichoscopy: relevance, clinical significance and peculiarities. Bras Dermatol. 2017;92(5):724\u20136.","journal-title":"Bras Dermatol"},{"issue":"2","key":"876_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000063908","volume":"205","author":"A Rebora","year":"2002","unstructured":"Rebora A, Guarrera M. Kenogen. A new phase of the hair cycle? Dermatology. 2002;205(2):108\u201310.","journal-title":"Dermatology"},{"key":"876_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/jcm13071962","volume":"13","author":"A Kuczara","year":"2024","unstructured":"Kuczara A, Waskiel-Burnat A, Rakowska A, Olszewska M, Rudnicka L. Trichoscopy of Androgenetic Alopecia: A Systematic Review. J Clin Med. 2024;13:7.","journal-title":"J Clin Med"},{"key":"876_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/OPTH.S6480","volume":"4","author":"SK Law","year":"2010","unstructured":"Law SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol. 2010;4:349\u201358.","journal-title":"Clin Ophthalmol"},{"key":"876_CR23","unstructured":"U.S. Food and Drug Administration. Medical Review(s): Latisse (bimatoprost ophthalmic solution) 0.03% (NDA 022369). Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration; 2008. Report No.: NDA 022369."},{"key":"876_CR24","unstructured":"Hopley CCS, Webster W, Bird G, Dillon E, Axford I. Prostaglandin analogues in cosmetics. Report No.: BEIS\/OPSS: RE21425; 2024."},{"key":"876_CR25","unstructured":"SCCS (Scientific Committee on Consumer Safety). Opinion on Prostaglandins and prostaglandin-analogues used in cosmetic products. European Commission, Directorate-General for Health and Food Safety. DG SANTE); 2022. Report No.: SCCS\/1635\/21."},{"key":"876_CR26","unstructured":"Safety SSCoC. Opinion on prostaglandin analogues used in cosmetic products. Report No.: SCCS\/1680\/25; 2025."},{"key":"876_CR27","unstructured":"EC. Commission Regulation (EU) 2025\/877 of 12 May 2025 amending Regulation (EC) 1223\/2009 of the European Parliament and of the Council as regards the use in cosmetic products of certain substances classified as carcinogenic, mutagenic or toxic for reproduction. 2025."}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00876-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00876-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00876-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:21:41Z","timestamp":1785856901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00876-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["876"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00876-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8949172\/v1","asserted-by":"object"}]},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A. Rakowska, L. Rudnicka, and K. Koziak are inventors on a patent related to the use of latanoprost acid for promoting hair growth. K. Koziak is a co-founder of BioResearch Pharma S.A. and serves as its Chief Scientific Officer. M. Wierzbicki is an employee of BioResearch Pharma S.A. (R&D Project Manager). BioResearch Pharma S.A. was incorporated several years after completion of the human study and therefore had no involvement in its design or conduct. The company provided partial financial support for selected in vitro analyses reported in this manuscript. The funders had no role in data analysis, interpretation, or the decision to submit the manuscript. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}